Design and rationale of the CLEAR SYNERGY (OASIS 9) trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone vs placebo in patients with myocardial infarction

Patients experiencing myocardial infarction (MI) remain at high risk of future major adverse cardiovascular events (MACE). While low-dose colchicine and spironolactone have been shown to decrease post-MI MACE, more data are required to confirm their safety and efficacy in an unselected post-MI popul...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American heart journal 2024-09, Vol.275, p.173-182
Hauptverfasser:	d'Entremont, Marc-André, Lee, Shun Fu, Mian, Rajibul, Kedev, Sasko, Montalescot, Gilles, Cornel, Jan Hein, Stankovic, Goran, Moreno, Raul, Storey, Robert F., Henry, Timothy D., Skuriat, Elizabeth, Tyrwhitt, Jessica, Mehta, Shamir R., Devereaux, P.J., Eikelboom, John, Cairns, John A., Pitt, Bertram, Jolly, Sanjit S.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiac arrhythmia Cardiovascular disease Cardiovascular diseases Cerebral infarction Clinical trials Colchicine Colchicine - administration & dosage Colchicine - therapeutic use Congestive heart failure Coronary vessels Death Double-Blind Method Drug dosages Ejection fraction Female Heart attacks Heart failure Humans Ischemia Male Medical research Middle Aged Mineralocorticoid Receptor Antagonists - administration & dosage Mineralocorticoid Receptor Antagonists - therapeutic use Mortality Multicenter Studies as Topic Myocardial Infarction Patients Percutaneous Coronary Intervention - methods Placebos Randomized Controlled Trials as Topic Spironolactone - administration & dosage Spironolactone - therapeutic use Stroke Vein & artery diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!